Related Experiment Videos
Neoadjuvant and adjuvant therapy for extremity soft tissue sarcomas
1Cancer Research-UK Centre for Cancer Therapeutics, Institute of Cancer Research, Sycamore House, Downs Road, Sutton, Surrey SM2 5PT, UK. michelle.scurr@icr.ac.uk
Hematology/Oncology Clinics of North America
|June 9, 2005
Summary
Adjuvant and neoadjuvant chemotherapy aim to cure localized soft tissue sarcoma (STS) by eliminating microscopic metastases. However, their effectiveness in improving survival for high-risk STS patients remains uncertain.
Area of Science:
- Oncology
- Surgical Oncology
- Medical Oncology
Background:
- Localized soft tissue sarcoma (STS) of the extremities generally has a good prognosis.
- However, high-risk STS patients face a significant risk of death from metastatic disease.
- Metastatic foci are often microscopic at diagnosis, necessitating treatment strategies to eradicate them.
Purpose of the Study:
- To review the evidence on the role of adjuvant and neoadjuvant chemotherapy in improving disease-specific survival for localized STS.
- To discuss the controversies surrounding the use of systemic chemotherapy in high-risk localized STS of the extremities.
Main Methods:
- Review of studies over the past 30 years investigating adjuvant and neoadjuvant chemotherapy for localized STS.
- Discussion of the current clinical management issues and controversies in STS treatment.
Main Results:
- Numerous studies have evaluated systemic chemotherapy for localized STS.
- The benefit of adjuvant or neoadjuvant chemotherapy in improving disease-specific survival for localized STS remains unclear.
- The role of systemic chemotherapy in high-risk localized STS is still debated.
Conclusions:
- The efficacy of systemic chemotherapy in improving cure rates for localized STS is not definitively established.
- Further research and discussion are needed to clarify the role of chemotherapy in managing high-risk localized STS.
- Management of high-risk localized STS remains a controversial area in oncology.